Krüppel‐like factor 5 (KLF5) is a member of the KLF family. Recent studies have suggested
that KLF5 regulates the expression of a large number of new target genes and participates …

Introduction The majority of breast cancers (BCs) are characterized by the expression of
estrogen receptor alpha (ERα+). ERα acts as ligand-dependent transcription factor for genes …

Breast cancer stem cells (BCSCs) represent a distinct subpopulation of cells with the ability
to self-renewal and differentiate into phenotypically diverse tumor cells. The involvement of …

As a new-generation CDK inhibitor, a CDK4/6 inhibitor combined with endocrine therapy
has been successful in the treatment of advanced estrogen receptor–positive (ER+) breast …

The Hippo pathway plays a critical role in cell growth and tumorigenesis. The activity of TEA
domain transcription factor 4 (TEAD4) determines the output of Hippo signaling; however …

Breast cancer (BC) is one of the most prominent diseases in the world, and the treatments
for BC have many limitations, such as resistance and a lack of reliable biomarkers. Currently …

Background Baculoviral inhibitor of apoptosis repeat-containing 5 or BIRC5, member of the
inhibitor of apoptosis (IAP), is a multitasking protein and among the top 100 deregulated …

The therapeutic mechanism of oleanolic acid (OA) in breast cancer has been widely
reported, but little has been known about the combined effects of transcriptome and gut …

The Hippo pathway is the major regulator of organ growth and proliferation. Described
initially in Drosophila, it is now recognized as one of the most conserved molecular …

Aims: Baculoviral inhibitor of apoptosis repeat containing 5 (BIRC5) plays vital roles in
carcinogenesis by influencing cell division and proliferation and by inhibiting apoptosis …